The second or third generation versions of the COVID-19 variant known as B.1.617 may already be circulating in India and may be more dangerous, says former Harvard Medical School professor William Haseltine.
"India has the necessary genome sequencing capabilities but it needs to have a mass surveillance program. I’ll be on the lookout for more and newer variants, given the opportunity the virus has had with such a massive outbreak," Bloomberg quoted Haseltine as saying who now chairs think tank Access Health International.
COVID-19 resurgence bringing renewed challenges for India; GDP growth seen at 9.5%: Fitch
The new observations which Prof Haseltine pointed out have more chances to be correct as the new variants of COVID-19 may be currently racing through India’s tightly-packed population of 1.4 billion people.
India on May 6 registered a record 412,262 new infections and 3,980 deaths. The country is under the grip of COVID-19 and have been adding over 300,000 cases for 15 straight days which has pushed its tally beyond 21 million.
With fears gripping the global arena over the new Indian variant of COVID-19, i.e. B.1.617, countries like Singapore, UK and Tanzania have curbed travel to and from India. Also, Australia has banned its citizens from returning from India and even imposed a fine of $50,000 and five years imprisonment for violators, reported the business daily.
Because of the presence of two changes in the virus’s genome, called E484Q and L452R, the India strain has been called a double mutant. As per research, these genome affect a portion of the spike protein which is the key to the virus entering cells.
Some of the researchers even estimate that Indian variant (B.1.617) is as transmissible as the UK variant (B.1.1.7) and may be 70 percent more transmissible than earlier versions of the virus.
However, initial analysis indicate that Indian variant (B.1.617) does not pose a big threat and doesn’t appear to be more dangerous. It has been now classified a variant of interest by the World Health Organization.
Hyderabad-bad based Centre for Cellular and Molecular Biology's Rakesh Mishra had said that Bharat Biotech's Covaxin and AstraZeneca Plc’s vaccine, called Covishield in India are effective against the strain.
Last week, BioNTech SE Chief Executive Officer Ugur Sahin opined that mRNA shot it’s making with partner Pfizer Inc. would work against the India mutant. "The Indian variant has the same mutation that we’ve already investigated and against which our vaccine was also effective," Sahin said.
Meanwhile, researchers are busy evaluating the data and findings of genomic surveillance which may help in providing crucial information on the new forms of this shape-shifting virus. This can even help in preventing subsequent waves and develop the next generation of vaccines.
WHO's technical lead officer Maria Van Kerkhove recently said that information about new variants is coming in 'fast and furious' as they are monitoring variants through a global working group of laboratories.
Looking at the current situation in India, the genomic sequencing which can identify new strains and track their progress is relatively sparse as only about 11,000 viruses have been analysed.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
